CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 143 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,829,000 | -16.6% | 279,218 | -15.3% | 0.04% | -44.6% |
| Q3 2020 | $2,192,000 | -26.5% | 329,556 | -8.0% | 0.07% | -31.5% |
| Q2 2020 | $2,983,000 | +46.4% | 358,122 | +34.8% | 0.11% | -1.8% |
| Q1 2020 | $2,038,000 | +59.5% | 265,673 | +72.7% | 0.11% | +86.4% |
| Q4 2019 | $1,278,000 | +12.9% | 153,818 | +0.3% | 0.06% | -4.8% |
| Q3 2019 | $1,132,000 | -31.5% | 153,397 | +4.2% | 0.06% | -24.4% |
| Q2 2019 | $1,652,000 | -1.7% | 147,223 | -5.9% | 0.08% | -8.9% |
| Q1 2019 | $1,681,000 | -31.9% | 156,391 | -4.4% | 0.09% | -48.6% |
| Q4 2018 | $2,470,000 | -20.1% | 163,547 | -2.1% | 0.18% | +4.2% |
| Q3 2018 | $3,091,000 | -16.8% | 167,088 | +2.8% | 0.17% | -25.0% |
| Q2 2018 | $3,715,000 | -19.7% | 162,504 | -0.1% | 0.22% | -32.9% |
| Q1 2018 | $4,626,000 | +140.4% | 162,592 | +78.4% | 0.33% | +121.2% |
| Q4 2017 | $1,924,000 | – | 91,144 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 524,763 | $7,924,000 | 3.84% |
| Congress Park Capital LLC | 123,311 | $1,862,000 | 2.05% |
| Perceptive Advisors | 2,911,715 | $43,588,000 | 1.66% |
| RTW INVESTMENTS, LP | 908,586 | $13,720,000 | 1.28% |
| HAMILTON LANE ADVISORS LLC | 68,753 | $1,038,000 | 0.91% |
| HARBOURVEST PARTNERS LLC | 79,193 | $1,196,000 | 0.57% |
| SPHERA FUNDS MANAGEMENT LTD. | 273,151 | $4,125,000 | 0.46% |
| Exane Asset Management | 50,000 | $755,000,000 | 0.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 622,548 | $9,400,000 | 0.38% |
| Cormorant Asset Management, LP | 296,712 | $4,480,000 | 0.36% |